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Table 1. Demographic and transplant details
No./Sex/Age (y) Diagnosis/Co-morbidities HLA match
TNC  107/kg
(cryopreserved)
Days to
ANC>500
Whole blood
chimerism/day post-tx Event Follow-up
1/M/2.03 MPS II / Cardiomyopathy 4/6 9.64 19 >98%/+623 A/W 655+
2/M/3.35 MPS IIIB 6/6 6.09 15 92%/+384 A/W 433+
3/F/3.32 MPS IIIB 5/6 6.08 28 63%/+112 Death 170
4/M/1.3 CHH 6/6 17.68 NE 0/+30 Graft failure 368+
5/M/6.76 MLD 5/6 5.88 24 >98%/+268 A/W 280+
6/F/3.32 Zap 70 def./Enteroviral meningitis, Resp.
MAI, Pseudomonas, Candida, Paraflu
5/6 8.3 21 >98%/+97 A/W 131+
7/F/0.45 HLH 5/6 22.27 19 >98%/+61 A/W 111+
8/F/0.58 HLH/Adenoviremia 4/6 14.19 20 >98%/+57 A/W 76+
Median: Age 2.67 8.97 20 280
MPS 5 mucopolysaccharidosis; CHH5Cartilage Hair Hypoplasia; MLD5Metachromatic Leukodystrophy; HLH5Hemophagocytic Lymphohistiocyto-
sis; NE5not evaluable; A/W5alive and well
S266 Poster Session Imelphalan (MEL) 140 mg/m2 and thiotepa (TT) 200mg/m2.
GVHD prophylaxis consisted of tacrolimus and MMF. All patients
received single UCBT; median age and weight at the time of trans-
plant were 3.3yrs and 15.1kg respectively; cryopreserved median cell
dose was 8.97x107 TNC/kg (range 5.9–22.3). HLA match was 4/6,
5/6 and 6/6 in 2, 4 and 2 patients respectively. Preparative regimen
was well tolerated. Maximummucositis was grade 3. To date, no pa-
tient has experienced CNS, cardiac, pulmonary or hepatorenal tox-
icity attributable to conditioning. Patient with Cartilage Hair
Hypoplasia (CHH) with no post-thaw CFU growth had autologous
recovery on day +30. He was successfully retransplanted with RIC
conditioning. The remaining patients (7 of 8) engrafted at a median
of 20 days post-transplant. At the last evaluation, whole blood donor
chimerism in engrafted patients ranged from 63% to . 98% with 6
of 7 engrafted patients. 90% donor. None of the patients have had
Grade 3-4 acute GVHD or extensive chronic GVHD thus far, al-
though follow-up for chronic GVHD is short. Untransfused platelet
count. 50K was achieved in all engrafted patients at a median of 39
days. Viral reactivation and/or de novo viral infections were seen
commonly but without appreciable end organ disease. Adenovirus
infection was noted in 5 patients (1 patient had adenoviremia that re-
solved with cidofovir and adoptive immunotherapy); the patient with
autologous recovery had prolonged CMV viremia. Seven of 8 pa-
tients are alive with a median follow-up of 280 days. One patient
with mixed chimerism died on day +170 of an acute hemolytic trans-
fusion reaction. The first two patients are off immunosuppression
with age appropriate immune profiles.
Conclusions: RIC with alemtuzumab, HU, FLU, MEL, TT is well
tolerated and results in a high rate of donor engraftment with a low
risk of GVHD and regimen related toxicity in children with chemo-
therapy na€ıve non-malignant diseases undergoing UCBT.308
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Prior to 2009, stable patients in our hematopoietic stem cell trans-
plant (HSCT) unit received routine transfusions for hemoglobin\9
g/dL. In February 2009, we changed this transfusion threshold to
Hgb\7 g/dL based on published data in critically ill but stable pe-
diatric intensive care unit patients. AIM: The aim of our study was to
assess the impact of changing to a conservative transfusion strategy in
children undergoing HSCT at our institution.
Methods:We compared census and transfusion data obtained dur-
ing primary admissions for HSCT using the prior transfusion
threshold (1/1/08-12/31/08) and after implementation of the conser-
vative transfusion threshold (3/1/09-2/28/10). All transfusion deci-
sions in both study periods were made at the discretion of
physician attendings. Data was analyzed with help from the PRU-
DENT quality improvement team, which focuses on PediatricResource Use and the Determination of Effective and Necessary
Targets at our hospital.
Results: 66 patients admitted for HSCT pre-intervention were
compared with 75 post-intervention. Pre-and post- patients were
of similar ages (median 6 (IQR 2, 12.5) vs. 6 (3, 13) yrs old, p 5
.8), and underwent similar types of transplant (22 (33%) vs. 26
(35%) autologous, p 5 .9), for similar diagnoses. Similar numbers
of patients received at least one transfusion in the two periods (65
(98.5%) vs. 72 (96%), p 5 .4). Post-intervention patients, however,
received significantly fewer RBC units (median 4 (IQR 3, 8) vs. 3
(2,5), p 5 .002) and had fewer transfusion days (median 4 (IQR
2, 5) vs. 3 (2, 5), p 5 .01). In addition, median Hgb pre-transfusion
significantly decreased from 8.8 g/dL to 6.8 g/dL (p \ .0001).
Patient outcomes appeared similar, with no differences in median
length of stay in days (37 (IQR 30, 46) vs. 37 (29, 52), p 5 .7),
median days to engraftment (20 (IQR 12, 25) vs. 18 (12, 24),
p 5 .7) or 100 Day Mortality (26% vs. 18%, p 5 .2). Finally,
median blood product related charges were significantly less
post-intervention ($3624 (IQR $2265, $6040) vs. $2185 ($1812,
$3997), p 5 .004).
Discussion: A review of our institutional experience suggests a con-
servative transfusion target of a Hgb of\7 g/dL in otherwise stable
children undergoing HSCT results in fewer transfusions without in-
creasing adverse outcomes. Further study is required to fully evaluate
the safety of this practice as well as to comprehensively assess its im-
pact on the provision of high-value, high-quality care in pediatric
HSCT units.309
CLONAL EVOLUTION IS A STRONGER PREDICTOR THAN DISEASE STATUS
OF DISEASE-FREE SURVIVAL AFTER PEDIATRIC HEMATOPOIETIC STEM
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Background: Clonal evolution as a model of tumor development
and progressionwas first proposed byNowell in 1976.Genetic insta-
bility of tumor cells leads to subpopulations with additional cytoge-
netic abnormalities. Subpopulations with cytogenetic abnormalities
that confer a survival advantage become the dominant population
leading to progression. Although clonal evolution has been generally
viewed as an adverse event, there is limited data regarding the effect
on outcome after HSCT.
Methods: We conducted a retrospective chart review of pediatric
patients who underwent HSCT for leukemia beyond CR1/CP1 or
with refractory disease from 2005-2010. Three patients with isolated
CNS relapse and two patients with JMML were excluded. Cytoge-
netic analyses from diagnosis and relapse were compared for 16 pa-
tients. Ten of these patients had clonal evolution, defined as an
additional cytogenetic abnormality from diagnosis. Relapse-free sur-
vival was analyzed using the Kaplan-Meier method and the differ-
ences between survival curves were tested using a log rank test at
a 0.05 significance level.
